Navigation Links
Global Cytomegalovirus Retinitis Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, Hospira and Shire

DUBLIN, Aug. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Cytomegalovirus Retinitis Market 2014-2018" report to their offering.

Cytomegalovirus retinitis is a viral eye inflammation of the retina. The causative organism of this disease is cytomegalovirus, a herpes virus that attacks the photosensitive cells in the retina. This disease can lead to permanent blindness if left untreated. It affects one eye initially but spreads to the other eye if neglected. The virus is very commonly found in humans but stays dormant. It usually affects a person with weakened immune system such as HIV-positive patients. There are two forms of cytomegalovirus retinitis: indolent form and fulminant form. Some of the common symptoms of cytomegalovirus retinitis are blurred vision, seeing floaters, photophobia, and blind spots.

The analysts forecast the Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018.

This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis.

The report, the Global Cytomegalovirus Retinitis market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cytomegalovirus Retinitis market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

An increase in combination therapies for the treatment of cytomegalovirus retinitis is a major trend emerging in the market. These therapies lower drug resistance in patients and ensure more effective action of the drug.

According to the report, the Global Cytomegalovirus Retinitis market is experiencing a large number of unmet needs. Currently, Roche's Valcyte is the only branded drug available for the treatment of this indication. The market has also observed the use of off-label drugs for the treatment of cytomegalovirus retinitis.

Further, the report states that one of the major challenges in the market is a lack of approved treatment guidelines by the WHO, which is responsible for the negligence of the treatment of cytomegalovirus retinitis worldwide.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Market Segmentation by Route of Administration

08. Market Segmentation by Dosage Form

09. Market Assessment of Valcyte

10. Rate of Incidence and Prevalence

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

20. Key Vendor Analysis

21. Other Reports in this Series

Companies Mentioned:

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Hospira
  • Shire
  • Auritec Pharmaceuticals
  • Chimerix Pharmaceuticals
  • Isis Pharmaceuticals
  • pSivida
  • Sanofi

For more information visit

Media Contact: Laura Wood, +353-1-481-1716,

SOURCE Research and Markets
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis
2. MNX Global Logistics renews multi-year contract with NuVasive, Inc.
3. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
4. Depomed To Present At Morgan Stanley 2014 Global Healthcare Conference
5. Cardiomyopathy Global Clinical Trials Review, H2, 2014
6. Vascular Dementias Global Clinical Trials Review, H2, 2014
7. Vocal Cord Paralysis Global Clinical Trials Review, H2, 2014
8. Traumatic Pain Global Clinical Trials Review, H2, 2014
9. Traumatic Spinal Cord Injury Global Clinical Trials Review, H2, 2014
10. Tremor Global Clinical Trials Review, H2, 2014
11. Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher
Post Your Comments:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
Breaking Medicine News(10 mins):